Non‑alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) have emerged as silent epidemics in the United States, affecting tens of millions of people, often without symptoms until advanced stages. These conditions do not develop in a vacuum. Instead, they are driven by a complex interplay between genetics,
In February, I wrote that 2025 would rhyme with 1926, the year when a volatile, skeptical market finally launched into the vertical phase of one of history’s greatest bull runs. By mid-year, that forecast has held: the spring correction shook out the weak hands, and U.S. equities have
Over the past two decades, breast cancer has surged in unexpected ways—particularly among young Asian American women. Once considered a lower-risk group, Asian American and Pacific Islander (AAPI) women are now seeing some of the fastest increases in breast cancer incidence in the United States. According to recent data,
Over the past 15 years, early-onset colorectal cancer (EOCRC), once a medical rarity, has exploded into a global public health crisis. Rates are climbing across nearly every major country, particularly among individuals aged 15 to 40. In fact, colorectal cancer is now on track to become the most diagnosed cancer
U.S. healthcare spending is on track to hit $7.7 trillion by 2032, a staggering and unsustainable figure. Yet emerging technologies in genetic stratification, remote biomarker monitoring, artificial intelligence, and targeted nutrition offer a potential paradigm shift. These tools offer a blueprint for cutting healthcare costs by as much
In today’s health care economy, there’s an uncomfortable truth that few want to say out loud: curing a patient is bad for business. The pharmaceutical industry, valued at over $1.5 trillion in 2023, is designed not to eliminate disease, but to manage it. Most new drugs approved
The markets are already amid an powerful bull market, that was initiated and carried along by the commercialization of Artificial Intelligence and large language models. However, it seems that the bull run is about to be accelerated by the convergence of AI, along with tokenization and quantum computing. Each has
When I first argued that 2025 would echo 1926, the bold claim centered on the markets. But now, it’s clear this isn’t just a bull market analog—it’s a geopolitical one too. Just like in the mid-1920s, the world is entering a lull in global conflict, a
Read the original forecast from February: https://ceobloc.com/blog/is-2025-the-next-1926-a-historic-bull-market-forecast As we cross into the second half of 2025, the stock market is increasingly validating a forecast that seemed bold at the start of the year: we are living through the modern equivalent of the "Roaring 1920s."
America is in the middle of a metabolic collapse. Over the past sixty years, obesity rates have more than tripled, and chronic diseases like diabetes, heart disease, and autoimmune disorders have become widespread. The usual explanations, overeating, sedentary lifestyles only scratch the surface. A deeper, largely ignored culprit is at
For decades, artificial sweeteners like aspartame and sucralose have been marketed as saviors in the fight against obesity, diabetes, and other metabolic diseases. With promises of zero calories and the ability to curb sugar cravings, these sweeteners have been embraced by consumers seeking healthier alternatives to sugar. But what if
In the 1920s, America cracked oil. In the 2020s, we’re about to crack the grid. A century ago, thermal cracking transformed crude into gasoline, unlocked affordable mobility, and powered one of the greatest economic expansions in human history. Factories scaled. Highways filled. Middle-class wealth exploded. Today, we’re witnessing